芪胶升白胶囊对曲妥珠单抗和多西紫杉醇治疗转移性乳腺癌的影响

Effect of Qijiao Shengbai capsule on trastuzumab and docetaxel in the treatment of metastatic breast cancer

目的探讨芪胶升白胶囊对曲妥珠单抗和多西紫杉醇治疗转移性乳腺癌的影响。方法选择我院肿瘤内科转移性乳腺癌患者100例,分为对照组与观察组,各50例。对照组给予曲妥珠单抗和多西紫杉醇治疗;观察组给予芪胶升白胶囊联合曲妥珠单抗和多西紫杉醇治疗:疗程均25周,疗程结束时观察两组临床疗效、生活质量和不良反应,并观察1年内生存情况。结果两组临床效果比较,差异无显著性(Z=-1.50,P>0.05);两组1年内生存情况比较,差异无显著性(χ2=1.00,P>0.05);两组生活质量比较,观察组高于对照组(t=2.37,P<0.05);两组治疗后骨髓抑制比较差异有显著性(χ2=4.76,P<0.05),而肝肾功能损害比较差异具有显著性(χ2=7.90,P<0.01)。结论芪胶升白胶囊可提高曲妥珠单抗和多西紫杉醇治疗转移性乳腺癌患者的生活质量,显著减轻化疗所引起的肝肾损伤和骨髓抑制。

Objective To investigate the effect of Qijiao Shengbai capsule on trastuzumab and docetaxel in the treatment of metastatic breast cancer.Methods 100 patients with metastatic breast cancer in the department of oncology in our hospital were selected and divided into the control group and the observation group,with 50 cases in each group.The control group was treated with trastuzumab and docetaxel,and the observation group was given Qijiao Shengbai capsule combined with trastuzumab and docetaxel.The course of treatment was 25 weeks.The clinical efficacy,quality of life and adverse reactions were observed at the end of the treatment.The survival within 1 year was observed.Results There was no significant difference in the clinical effect between the two groups(Z=-1.50,P>0.05).There was no significant difference in survival between the two groups within 1 year(χ2=1.00,P>0.05).The quality of life of the observation group was higher than that of the control group(t=2.37,P<0.05).There was significant difference in bone marrow suppression between the two groups after treatment(χ2=4.76,P<0.05),and the difference in liver and kidney function damage was more significant(χ2=7.90,P<0.01).Conclusion Qijiao Shengbai capsule can improve the quality of life of metastatic breast cancer treated with trastuzumab and docetaxel,and significantly reduce liver and kidney damage and bone marrow suppression caused by chemotherapy.